On February 19, 2026, the United States Court of Appeals for the Federal Circuit ruled that Teva’s marketing of a generic version of Corcept Therapeutics’ Korlym does not infringe two of Corcept’s patents covering safe co‑administration with CYP3A4 inhibitors. The decision removes a key patent protection that Corcept had relied on to defend its single‑product revenue stream.
The patents at issue are U.S. Patent Nos. 10,195,214 and 10,842,800. The Federal Circuit’s ruling confirms a prior district court decision issued on December 29, 2023, and clears a major legal hurdle for Teva, which received FDA approval for a generic version of Korlym in August 2020. The Cushing’s syndrome diagnostics and therapeutics market was valued at approximately $418.21 million in 2026 and is projected to reach $648.79 million by 2031, growing at a CAGR of 9.18%.
Corcept’s Korlym generated about $675 million in annual revenue in 2025, and the loss of patent protection threatens to erode that stream as generic competition accelerates. The company reported cash and investments of $603.2 million as of December 31 2024, with $524 million in liquidity, giving it a runway to finance its oncology pipeline, particularly relacorilant, which is now the focus after a Complete Response Letter for hypercortisolism in late 2025.
In a statement, Corcept CEO Joseph K. Belanoff said, “We are disappointed in the Court’s ruling. The patents we asserted in this case cover methods of safely treating patients with Cushing’s syndrome that physicians rely on every day. We will vigorously defend our rights and are currently considering the best way to pursue judicial review of this decision.”
The ruling signals a significant shift in the competitive landscape for Cushing’s syndrome treatment. With the legal barrier removed, Teva’s generic Korlym can enter the market sooner, potentially capturing market share and pressuring Corcept’s pricing power. The decision also underscores the vulnerability of single‑product companies to patent litigation outcomes and highlights the importance of diversifying product portfolios.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.